FrancophonIA/ELRC3.0 huggingface dataset:
English: Subcutaneous tolerance studies indicate that Caelyx, as against standard doxorubicin hydrochloride, causes slighter local irritation or damage to the tissue after a possible extravasation.
Croatian: Ispitivanja potkožne podnošljivosti pokazuju da Caelyx, nasuprot standardnom doksorubicinkloridu, uzrokuje blažu lokalnu nadraženost ili oštećenje tkiva nakon eventualne ekstravazacije.
English: Evidence of penetration of pegylated liposomes from blood vessels and their entry and accumulation in tumours has been seen in mice with C-26 colon carcinoma tumours and in transgenic mice with KS-like lesions.
Croatian: Prodiranje pegiliranih liposoma iz krvnih žila i njihov ulazak i nakupljanje u tumoru dokazano je u miševa s C-26 karcinomima debelog crijeva i u transgeničnih miševa s lezijama sličnim Kaposijevom sarkomu.
English: Given the difference in pharmacokinetic profiles and dosing schedules, Caelyx should not be used interchangeably with other formulations of doxorubicin hydrochloride.
Croatian: S obzirom na razlike u farmakokinetičkom profilu i rasporedu doziranja, Caelyx se ne smije naizmjenično primjenjivati s drugim oblicima doksorubicinklorida.
English: In repeat dose studies conducted in animals, the toxicity profile of Caelyx appears very similar to that reported in humans who receive long-term infusions of standard doxorubicin hydrochloride.
Croatian: U ispitivanjima toksičnosti ponovljene doze na životinjama, profil toksičnosti Caelyxa čini se vrlo sličnim profilu zabilježenom u ljudi koji dugotrajno primaju infuzije standardnog doksorubicinklorida.
English: Mucositis (23% vs. 13%; grade 3/4 4% vs. 2%), and stomatitis (22% vs. 15%; grade 3/4 5% vs. 2%) were reported more commonly with Caelyx than with doxorubicin.
Croatian: Mukozitis (23% naspram 13%; stupanj 3/4 4% naspram 2%) i stomatitis (22% naspram 15%; stupanj 3/4 5% naspram 2%) bili su češći uz Caelyx nego uz doksorubicin.
English: Type I glass vials, each with a siliconised grey bromobutyl stopper, and an aluminium seal, with a deliverable volume of 10 ml (20 mg) or 25 ml (50 mg).
Croatian: Bočice od stakla tipa I, svaka sa silikoniziranim sivim brombutilnim čepom i aluminijskim prstenom, s volumenom lijeka za primjenu od 10 ml (20 mg) ili 25 ml (50 mg).
English: The doctor may wish to delay the start and/or reduce the dose of the next treatment (see Strategies to prevent and treat hand-foot syndrome, below); - pain or sores in mouth or throat, nausea, vomiting, diarrhoea, constipation, loss of appetite, weight loss; - decrease in the number of white blood cells, which can increase the chances of infections.
Croatian: Liječnik će možda željeti odgoditi početak i/ili smanjiti dozu sljedećeg ciklusa (vidjeti Strategije za sprječavanje i liječenje sindroma šakastopalo, niže); - bol ili ranice u ustima ili grlu, mučnina, povraćanje, proljev, zatvor, gubitak apetita, smanjenje tjelesne težine - smanjenje broja bijelih krvnih stanica, što može povećati mogućnost infekcije.
English: Common adverse events which led to treatment discontinuation of bortezomib and Caelyx included PPE, neuralgia, peripheral neuropathy, peripheral sensory neuropathy, thrombocytopaenia, decreased ejection fraction, and fatigue.
Croatian: Česte nuspojave, koje su dovele do prekida liječenja bortezomibom i Caelyxom, uključivale su PPE, neuralgiju, perifernu neuropatiju, perifernu senzornu neuropatiju, trombocitopeniju, smanjenu ejekcijsku frakciju i umor.
English: If tolerated without reaction, the infusion rate was doubled for the next 15 minutes.
Croatian: Ako se to podnijelo bez reakcije, brzina infuzije je udvostručena tijekom sljedećih 15 minuta.
English: Caelyx must not be given by the intramuscular or subcutaneous route.
Croatian: Caelyx se ne smije davati intramuskularnim ili supkutanim putem.
English: Caelyx is also used in combination with another medicine, bortezomib, to treat multiple myeloma, a cancer of the blood in patients who have received at least 1 prior therapy.
Croatian: Caelyx se također primjenjuje u kombinaciji s drugim lijekom, bortezomibom, u liječenju multiplog mijeloma, raka krvi kod bolesnika koji su prethodno primili barem 1 liniju liječenja.
English: Women of child-bearing potential must be advised to avoid pregnancy while they or their male partner are receiving Caelyx and in the six months following discontinuation of Caelyx therapy (see section
Croatian: Ženama u reproduktivnoj dobi potrebno je savjetovati izbjegavanje trudnoće dok one ili njihov muški partner primaju Caelyx te tijekom šest mjeseci nakon prestanka terapije Caelyxa (vidjeti dio 5.3).
English: Very common (≥ 1/10); Common (≥ 1/100, < 1/10); Uncommon (≥ 1/1,000, < 1/100) Infections and infestations common oral moniliasis
Croatian: vrlo često (> 1/10); često (> 1/100, < 1/10); manje često (> 1/1000, < 1/100) Infekcije i infestacije često oralna monilijaza
English: Exercise caution in the concomitant use of medicinal products known to interact with standard doxorubicin hydrochloride.
Croatian: Budite oprezni kod istovremene primjene lijekova za koje se zna da ulaze u interakciju sa standardnim doksorubicinkloridom.
English: Caelyx is indicated: - As monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk.
Croatian: Caelyx je indiciran: - Kao monoterapija u bolesnika s metastatskim karcinomom dojke kod kojih postoji povećani rizik od srčanih poremećaja.
English: The evaluation tests and methods mentioned above concerning the monitoring of cardiac performance during anthracycline therapy are to be employed in the following order: ECG monitoring, measurement of left ventricular ejection fraction, endomyocardial biopsy.
Croatian: Gore spomenute pretrage i postupci praćenja rada srca tijekom liječenja antraciklinima primjenjuju se sljedećim redoslijedom: EKG pregled, mjerenje ejekcijske frakcije lijeve klijetke, biopsija endomiokarda.
English: Treatment of acute overdose of the severely myelosuppressed patient consists of hospitalisation, antibiotics, platelet and granulocyte transfusions and symptomatic treatment of mucositis.
Croatian: Liječenje akutnog predoziranja teško mijelosuprimiranih bolesnika sastoji se od hospitalizacije, antibiotika, transfuzija trombocita i granulocita i simptomatskog liječenja mukozitisa.
English: Bortezomib
Croatian: Caelyx bortezomib
English: Caution must be exercised in handling Caelyx solution.
Croatian: Potreban je oprez kod rukovanja otopinom Caelyxa.
English: This allows the Caelyx liposomes to circulate for prolonged periods in the blood stream.
Croatian: To omogućuje liposomima Caelyxa da dulje vrijeme cirkuliraju krvotokom.
English: - taking cool baths during hot weather; - avoiding vigorous exercise that might cause trauma to the feet (e.g., jogging); - avoiding exposure of skin to very hot water (e.g., jacuzzis, saunas); - avoiding tight fitting footwear or high-heeled shoes.
Croatian: - boravak u hladnim prostorima; - primjena hladnih kupki tijekom toplog vremena; - izbjegavanje intenzivnog vježbanja kojim možete ozlijediti stopala (npr., trčanje); - izbjegavanje izlaganja kože jako vrućoj vodi (npr., jacuzzi, sauna); - izbjegavanje uske obuće ili cipela s visokim potpeticama.
English: The median OS was 30.8 months (95% CI; 25.2-36.5 months) for the bortezomib monotherapy patients and 33.0 months (95% CI; 28.9-37.1 months) for the Caelyx plus bortezomib combination therapy patients.
Croatian: Medijan OS bio je 30,8 mjeseci (95% CI: 25,2-36,5 mjeseci) za bolesnike na monoterapiji bortezomibom i 33,0 mjeseci (95% CI: 28,9-37,1 mjeseci) za bolesnike na kombiniranom liječenju Caelyxom s bortezomibom.
English: To minimise the risk of infusion reactions, the initial dose is administered at a rate no greater than 1 mg/minute.
Croatian: Da bi se minimalizirao rizik od reakcije na infuziju, početna doza primjenjuje se brzinom koja nije veća od 1 mg u minuti.
English: Caelyx concentrate for solution for infusion: vials which provide 10 ml (20 mg) or 25 ml (50 mg).
Croatian: Caelyx koncentrat za otopinu za infuziju: bočice koje sadrže 10 ml (20 mg) ili 25 ml (50 mg).
English: Respiratory undesirable effects commonly occurred in clinical studies of Caelyx and may be related to opportunistic infections (OI's) in the AIDS population.
Croatian: Nuspojave dišnog sustava bile su česte u kliničkim ispitivanjima Caelyxa i mogu biti povezane s oportunističkim infekcijama (OI, od engl. opportunistic infections) u populacije s AIDS-om.
English: Multiple myeloma program
Croatian: Program liječenja multiplog mijeloma
English: If the patient experiences early symptoms or signs of infusion reaction (see sections 4.4 and 4.8), immediately discontinue the infusion, give appropriate premedications (antihistamine and/or short acting corticosteroid) and restart at a slower rate.
Croatian: Ako bolesnik pokazuje rane simptome ili znakove reakcije na infuziju (vidjeti dijelove 4.4 i 4.8), odmah prekinite infuziju i primijenite odgovarajuću premedikaciju (antihistaminik i/ili kratkodjelujući kortikosteroid) te nastavite s infuzijom, ali smanjite brzinu protoka.
English: Neuropathic pain or peripheral neuropathy
Croatian: Neuropatska bol ili periferna neuropatija
English: Psychiatric disorders uncommon confusion
Croatian: Psihijatrijski poremećaji manje često konfuzija
English: G-CSF (or GM-CSF) may be given as concomitant therapy to support the blood count when the ANC count is < 1,000/mm
Croatian: U sljedećim se ciklusima može istovremeno dati G-CSF (ili GM-CSF) kako bi se poboljšala krvna slika kad je ANC < 1.000/mm
English: A study has shown that Caelyx at a single intravenous dose of over twice the clinical dose produces renal toxicity in monkeys.
Croatian: Ispitivanje je pokazalo da Caelyx u jednokratnoj intravenskoj dozi koja je više nego dvaput veća od kliničke doze toksično djeluje na bubrege u majmuna.
English: Prior to Caelyx administration, evaluate hepatic function using conventional clinical laboratory tests such as ALT/AST, alkaline phosphatase, and bilirubin.
Croatian: Prije primjene Caelyxa, provjerite funkciju jetre pomoću uobičajenih laboratorijskih pretraga, kao što su određivanje ALT/AST, alkalne fosfataze i bilirubina.
English: In the pivotal trial in patients with ovarian cancer treated at a dose of 50 mg/m myelosuppression was generally mild to moderate, reversible, and was not associated with episodes of neutropaenic infection or sepsis.
Croatian: U pivotalnom kliničkom ispitivanju u bolesnica s karcinomom jajnika liječenih dozom od 50 mg/m2 mijelosupresija je općenito bila blaga do umjerena, reverzibilna i nije bila povezana s epizodama neutropenijske infekcije ili sepse.
English: The pharmacokinetic parameters of Caelyx (primarily representing pegylated liposomal doxorubicin hydrochloride and low levels of unencapsulated doxorubicin hydrochloride) observed after the 20 mg/m2 doses are presented in
Croatian: Farmakokinetički parametri Caelyxa (koji primarno predstavljaju pegilirani liposomalni doksorubicinklorid i niske razine neinkapsuliranog doksorubicinklorida) izmjereni nakon doze od 20 mg/m2 prikazani su u tablici 10.
English: Solid tumour patients: in a larger cohort of 929 patients with solid tumours (including breast cancer and ovarian cancer) predominantly treated at a dose of 50 mg/m2 every 4 weeks, the safety profile and incidence of adverse effects are comparable to those of the patients treated in the pivotal breast cancer and ovarian cancer trials.
Croatian: Bolesnice sa solidnim tumorima: u većoj kohorti od 929 bolesnica sa solidnim tumorima (uključujući karcinom dojke i karcinom jajnika), pretežno liječenih dozom od 50 mg/m svaka 4 tjedna, sigurnosni profil i incidencija nuspojava bile su usporedive s onima u bolesnica liječenih u pivotalnim ispitivanjima karcinoma dojke i karcinoma jajnika.
English: In patients with multiple myeloma receiving Caelyx plus bortezomib, infusion-associated reactions have been reported at a rate of 3%.
Croatian: U bolesnika s multiplim mijelomom koji su primali Caelyx i bortezomib, reakcije povezane s infuzijom zabilježene su s učestalošću od 3%.
English: Caelyx resulted in mild to moderate ovarian and testicular atrophy in mice after a single dose of 36 mg/kg.
Croatian: Caelyx je izazvao blagu do umjerenu atrofiju jajnika i testisa u miševa nakon jednokratne doze od 36 mg/kg.
English: 512 patients with ovarian cancer (a subset of 876 solid tumour patients) were treated with Caelyx at a dose of 50 mg/m2 in clinical trials.
Croatian: 512 bolesnica s karcinomom jajnika (podskupina od 876 bolesnica sa solidnim tumorom) primalo je Caelyx u dozi od 50 mg/m2 u kliničkim ispitivanjima.
English: Redose unless patient has experienced a previous grade 3 or 4 stomatitis in which case wait an additional week
Croatian: Ponoviti dozu osim ako je bolesnik prethodno imao stomatitis 3. ili 4. stupnja, u tom slučaju potrebno je pričekati još jedan tjedan
English: The use of any diluent other than 5% (50 mg/ml) glucose solution for infusion, or the presence of any bacteriostatic agent such as benzyl alcohol may cause precipitation of Caelyx.
Croatian: Uporaba bilo kojeg drugog otapala osim 5%-tne (50 mg/ml) otopine glukoze za infuziju ili prisutnost bilo kakvog bakteriostatskog sredstva, kao što je benzilni alkohol, može izazvati precipitaciju lijeka Caelyx.
English: Paresthesia, somnolence
Croatian: Manje često parestezija, somnolencija
English: The following common adverse events were reported more often with doxorubicin than with Caelyx: nausea (53% vs. 37%; grade 3/4 5% vs. 3%), vomiting (31% vs. 19%; grade 3/4 4% vs. less than 1%), any alopecia (66% vs. 20%), pronounced alopecia (54% vs.7%), and neutropaenia (10% vs. 4%; grade 3/4 8% vs.
Croatian: Sljedeće su nuspojave bile učestalije s doksorubicinom nego s Caelyxom: mučnina (53% naspram 37%; stupanj 3/4 5% naspram 3%), povraćanje (31% naspram 19%; stupanj 3/4 4% naspram manje od 1%), bilo kakva alopecija (66% naspram 20%), izražena alopecija (54% naspram 7%), i neutropenija (10% naspram 4%; stupanj 3/4 8% naspram 2%).
English: Many patients treated with Caelyx have baseline myelosuppression due to such factors as their pre-existing HIV disease or numerous concomitant or previous medications, or tumours involving bone marrow.
Croatian: Mnogi bolesnici koji se liječe Caelyxom na početku liječenja imaju mijelosupresiju zbog čimbenika kao što su postojeća infekcija HIV-om ili brojni lijekovi koje uzimaju istovremeno ili su ih prije uzimali, ili tumori koji zahvaćaju koštanu srž.
English: Dose modification in patients with AIDS-KS is addressed in section 4.8.
Croatian: Prilagodba doze u bolesnika s Kaposijevim sarkomom povezanim s AIDS-om prikazana je u dijelu 4.8.
English: Although no studies have been conducted with Caelyx, doxorubicin hydrochloride, the pharmacologically active ingredient of Caelyx, is mutagenic and carcinogenic.
Croatian: Premda ova ispitivanja nisu provedena s Caelyxom, doksorubicinklorid, farmakološki djelatan sastojak Caelyxa, mutagen je i kancerogen.
English: The dose should be repeated as long as patients respond satisfactorily and tolerate treatment.
Croatian: Ovu dozu treba ponavljati sve dok bolesnici pokazuju zadovoljavajući terapijski odgovor i podnose liječenje.
English: Doxorubicin becomes available after the liposomes are extravasated and enter the tissue compartment.
Croatian: Doksorubicin se oslobađa nakon što liposomi izađu iz krvotoka i uđu u tkivo.
English: Adverse drug reactions identified during the post-marketing experience with Caelyx are described in Table 9.
Croatian: Nuspojave identificirane nakon stavljanja lijeka Caelyx u promet opisane su u Tablici 9.
English: Uncommon  1/1,000 and < 1/100 Rare
Croatian: Manje često  1/1000 i < 1/100
English: If tolerated, the infusion was completed over the next hour for a total infusion time of 90 minutes.
Croatian: Ako se i to podnijelo, infuzija je dovršena tijekom sljedećih sat vremena tako da je ukupno trajanje infuzije bilo 90 minuta.
English: The dose is repeated as long as you respond satisfactorily and tolerate treatment.
Croatian: Doza se ponavlja sve dok imate zadovoljavajući odgovor na liječenje i dobro ga podnosite.
English: Guidelines for Caelyx dose modification
Croatian: Smjernice za prilagodbu doze Caelyxa
English: Animal studies indicate that administration of doxorubicin hydrochloride as a liposomal formulation reduces the potential for extravasation injury.
Croatian: Ispitivanja na životinjama pokazuju da primjena doksorubicinklorida u liposomalnom obliku smanjuje mogućnost oštećenja zbog ekstravazacije.
English: Breast cancer/Ovarian cancer Caelyx is administered intravenously at a dose of 50 mg/m once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment.
Croatian: Karcinom dojke/karcinom jajnika Caelyx se primjenjuje intravenski u dozi od 50 mg/m jedanput svaka 4 tjedna, do progresije bolesti odnosno dok bolesnik podnosi liječenje.
English: - In combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.
Croatian: - U kombinaciji s bortezomibom za liječenje progresivnog multiplog mijeloma u bolesnika koji su prethodno primili najmanje jednu liniju liječenja i koji su prošli presađivanje koštane srži ili za isto nisu bili pogodni.
English: The table for haematological toxicity (Table 3) provides the schedule followed for dose modification in clinical trials in the treatment of patients with breast or ovarian cancer only.
Croatian: Tablica za hematološku toksičnost (tablica 3) prikazuje način prilagodbe doze primjenjen u kliničkim ispitivanjima liječenja bolesnika s karcinomom dojke ili jajnika.
English: In contrast, 10 of 48 doxorubicin subjects who had cardiac toxicity by LVEF criteria also developed signs and symptoms of CHF.
Croatian: Nasuprot tomu, 10 od 48 ispitanika liječenih doksorubicinom koji su pokazivali znakove kardiotoksičnosti prema LVEF kriterijima razvilo je i znakove i simptome kroničnog zatajenja srca.
English: Do not dose this cycle if before day 4; if after day 4 reduce next dose by 25% in the following cycles if bortezomib is reduced for haematologic toxicity.
Croatian: Nemojte primijeniti dozu u ovom ciklusu ako su navedene nuspojave uočene prije 4. dana ciklusa; ako se jave nakon 4. dana, smanjite sljedeću dozu za 25% u sljedećim ciklusima ako je doza bortezomiba smanjena zbog hematološke toksičnosti.*
English: A phase III randomised, parallel-group, open-label, multicentre study comparing the safety and efficacy of Caelyx plus bortezomib combination therapy with bortezomib monotherapy in patients with multiple myeloma who have received at least 1 prior therapy and who did not progress while receiving anthracycline-based therapy, was conducted in 646 patients.
Croatian: Randomizirano, multicentrično ispitivanje faze III otvorenog tipa na usporednim skupinama kojim se uspoređivala djelotvornost i sigurnost primjene kombiniranog liječenja Caelyxom i bortezomibom s monoterapijom bortezomibom u bolesnika s multiplim mijelomom koji su prethodno primili barem 1 liniju liječenja i u kojih bolest nije napredovala za vrijeme liječenja antraciklinima, uključilo je 646 bolesnika.
English: How much Caelyx is given
Croatian: Koliko Caelyxa se daje
English: Do not use with in-line filters.
Croatian: Nemojte koristiti infuzijske cijevi s ugrađenim filtrima.
English: Ovarian cancer n=512
Croatian: Karcinom jajnika n=512
English: Do not dose until recovered to grade < 2 and reduce dose by 25% for all subsequent doses.
Croatian: Nemojte primijeniti dozu prije oporavka do < 2. stupnja toksičnosti i smanjite sve sljedeće doze za 25%.
English: The treatments were similar in the sub-group of patients with platinum-refractory disease: HR of 1.069 (95% CI: 0.823; 1.387), p=0.618.
Croatian: Liječenje je bilo slično u podskupini bolesnica otpornih na platinu: HR od 1,069 (95% CI: 0,823; 1,387), p=0,618.
English: The active ingredient of Caelyx is doxorubicin hydrochloride, a cytotoxic anthracycline antibiotic obtained from Streptomyces peucetius var. caesius.
Croatian: Djelatna tvar u Caelyxu je doksorubicinklorid, citotoksični antraciklinski antibiotik koji se dobiva iz Streptomyces peucetius var. caesius.
English: Aseptic technique must be strictly observed since no preservative or bacteriostatic agent is present in Caelyx.
Croatian: Morate se strogo pridržavati aseptične tehnike, budući da Caelyx ne sadrži nikakav konzervans niti bakteriostatsko sredstvo.
English: Caution must be exercised when giving any other cytotoxic agents, especially myelotoxic agents, at the same time.
Croatian: Potreban je oprez pri istovremenoj primjeni drugih citotoksičnih sredstava, osobito onih mijelotoksičnih..
English: The cardiac safety profile for the dosing schedule recommended for both breast and ovarian cancer (50 mg/m 2) is similar to the 20 mg/m 2 profile in patients with AIDS-KS (see section 4.8).
Croatian: Kardiološki sigurnosni profil kod preporučenog rasporeda doziranja za karcinom dojke i karcinom jajnika (50 mg/m2) sličan je sigurnosnom profilu doze od 20 mg/m u bolesnika s Kaposijevim sarkomom povezanim s AIDS-om (vidjeti dio 4.8).
English: - For treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.
Croatian: - Za liječenje uznapredovalog karcinoma jajnika u žena u kojih liječenje prvom linijom kemoterapije na bazi platine nije bilo uspješno.
English: Patient status
Croatian: Stanje bolesnika
English: A similar low incidence of myelosuppression was seen in patients with metastatic breast cancer receiving Caelyx in a first-line clinical trial.
Croatian: Slično niska incidencija mijelosupresije nađena je u bolesnica s metastatskim karcinomom dojke koje su primale Caelyx kao prvu liniju u kliničkom ispitivanju.
English: Caelyx is a unique formulation.
Croatian: Caelyx je jedinstveni oblik lijeka.
English: If the patient experiences early symptoms or signs of infusion reaction, immediately discontinue the infusion, give appropriate premedications (antihistamine and/or short acting corticosteroid) and restart at a slower rate.
Croatian: Ako bolesnik osjeti rane simptome i znakove reakcije na infuziju, odmah prekinite infuziju, primijenite odgovarajuću premedikaciju (antihistaminik i/ili kratkodjelujući kortikosteroid) i nastavite infuziju smanjenom brzinom protoka.
English: Of the 418 patients treated with Caelyx 50 mg/m2/cycle, and having a baseline measurement of left ventricular ejection fraction (LVEF) and at least one follow-up measurement assessed by MUGA scan, 88 patients had a cumulative anthracycline dose of > 400 mg/m2, an exposure level associated with an increased risk of cardiovascular toxicity with conventional doxorubicin.
Croatian: Od 418 bolesnika liječenih Caelyxom u dozi od 50 mg/m2 po ciklusu, kojima je na početku ispitivanja izmjerena ejekcijska frakcija lijeve klijetke (LVEF) i učinjeno najmanje jedno MUGA mjerenje tijekom praćenja, 88 bolesnika primilo je kumulativnu dozu antraciklina od > 400 mg/m2, što predstavlja razinu izloženosti povezanu s povećanim rizikom od kardiovaskularne toksičnosti kod konvencionalnog doksorubicina.
English: Caelyx can be administered to patients with liver metastases with concurrent elevation of bilirubin and liver enzymes up to 4 x the upper limit of the normal range.
Croatian: Caelyx se može primijeniti u bolesnika s metastazama u jetri i istovremeno povišenom razinom bilirubina i jetrenih enzima do 4 puta iznad gornje granice normale.
English: Leukopaenia is the most frequent undesirable effect experienced with Caelyx in this population; neutropaenia, anaemia and thrombocytopaenia have been observed.
Croatian: Leukopenija je najčešća nuspojava Caelyxa u ove populacije; primijećene su i neutropenija, anemija i trombocitopenija.
English: Acute overdosing with doxorubicin hydrochloride worsens the toxic effects of mucositis, leukopaenia and thrombocytopaenia.
Croatian: Akutno predoziranje doksorubicinkloridom pogoršava toksične učinke mukozitisa, leukopenije i trombocitopenije.